Amgen INC DEF 14A proxy statements

Amgen Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 19, 2026, detailing strong 2025 performance in drug development, sales growth, and manufacturing investments.

Amgen reports record sales for multiple products, advancements in its research and development pipeline, and outlines key board recommendations for the upcoming annual meeting.

Amgen's 2025 proxy statement highlights a strong 2024 with record sales for many products and outlines key initiatives, including advancing clinical trials and expanding manufacturing capacity.

Amgen Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 23, 2025, with key proposals including the election of twelve directors, approval of executive compensation, and ratification of Ernst & Young LLP as independent accountants.

Amgen's 2025 proxy statement details the agenda for the annual meeting and highlights the company's strong 2024 performance, including record sales and pipeline advancements.

Amgen is reminding stockholders to vote on key proposals ahead of the Annual Meeting of Stockholders scheduled for May 31, 2024.

Amgen encourages stockholders to vote in line with the Board's recommendations at the upcoming Annual Meeting, highlighting the company's strategic execution, commitment to society, and corporate governance practices.

Amgen's proxy statement emphasizes its strategic focus on innovation, the acquisition of Horizon Therapeutics, and commitment to environmental and social goals.

Amgen Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 31, 2024, with stockholders voting on the election of directors, executive compensation, an equity incentive plan, and the ratification of the company's independent auditor.

Amgen's 2024 proxy statement outlines key proposals for the annual meeting, including director elections, executive compensation approval, and an amendment to the equity incentive plan.